News

NeedleSmart PRO Receives FDA Approval

NeedleSmart PRO Receives FDA Approval
Covid-19
Member News

The award-winning NeedleSmart PRO needle destruction device has achieved FDA approval as a Class II medical device.

Merseyside Based NeedleSmart Ltd is the FIRST UK company to achieve FDA 510(k) approval (Class II for Sharps Needle Destruction Device (NDD).

The innovative NeedleSmart PRO device heats a sharp, contaminated hypodermic needle to 1,300, then compresses the molten metal into a smooth ball at the end of the syringe, removing the danger of needlestick injury and infection in just 6 seconds.

NeedleSmart’s patented technology is engineered in the UK, with offices in Knowsley, Merseyside (UK), and recently opened Pittsburgh, Pennsylvania (USA).

The NeedleSmart PRO will be used in clinical environments including hospitals and GP surgeries, and will be used in digital vaccination programmes and immunisations based in the North West.

The device offers many benefits

  • Reduction of needlestick injuries (NSI) and associated costs both emotional and financial.
  • Sustainability approx. 25% reduction in sharps bin requirement, leading to less waste, and contributing to the overall carbon footprint in the medical sector.
  • Potential introduction of clinisafe bag/box as no longer a sharp.
  • Along with associated software, the device will be used to digitalise vaccination data seamlessly, securely and safely.

Merseyside based NeedleSmart CEO Cliff Kirby added: “I am absolutely thrilled that the NeedleSmart PRO has received FDA approval. Knowing we are the first UK Company to achieve this is a fantastic achievement and pays testament to the product and expertise of our team, and we are looking forward new distribution partnerships in the USA.”

NeedleSmart is a smart med-tech business focused on better health results including safety, clinical process efficiency, cost management, and digitisation of clinical events, whilst improving sustainability. FDA approval marks a milestone in NeedleSmart’s geographic expansion to serve the North American market.

For more information & images please contact:

julie@needlesmart.com

+44 (0)7850630004

T: +44 (0)151 315 0500 (UK)

T: +1 (717) 8561296 (USA)

needlesmart.com

digitalvaccination.com

NEWS​

Related News

Accelerate Your Health Innovations with ECHAlliance

25 Jul 2024
Join ECHAlliance to scale your health solutions through our extensive network.

July 2024 ECHAlliance Newsletter

24 Jul 2024

Cross-sector collaboration positions West Yorkshire as global leader in healthtech innovation

24 Jul 2024
West Yorkshire’s health, care and academic leaders signed a Memorandum of Understanding with with the Association of British HealthTech Industries (AB...

Strata Health Launches Booking and Referral Standard (BaRS) at NHS East Lancashire Hospitals

24 Jul 2024
Thousands of referrals have passed through our integration to create appointments in Strata PathWays, which has already made a huge impact within the ...

Envisioning seamless sharing of digital meds data in Wales

24 Jul 2024
Digital Health and Care Wales (DHCW) is embarking on the creation of a shared medicines record for the whole of the country. The Digital Medicines Tra...

One of Europe’s leading university hospitals selects Better technology for its core data platform

24 Jul 2024
Following a framework procurement issued in 2023, one of Europe's leading university hospitals has completed the first call-off for openEHR software, ...

Become a member

Join ECHAlliance to amplify your organisation’s message, grow your networks, connect with innovators and collaborate globally.
 
First name *
Last Name *
Email Address *
Country *
Position *
First name *
Last Name *
Email Address *
Country *
Position *